Skip to main content

Table 2 Pooled analysis of functional class, exercise capacity, quality of life, and clinical outcome

From: Safety and efficacy of bone marrow-derived cells therapy on cardiomyopathy: a meta-analysis

 

No. of studies

Mean difference/risk ratio

95% CI

P

6-min walk distance

 Overall

9

53.13

25.47, 81.10

0.0002

 3 months

6

47.92

7.95, 87.89

0.02

 6 months

8

49.68

3.34, 96.01

0.04

 ≥ 12 months

6

63.91

0.06, 127.76

0.05

NYHA functional class

 Overall

6

− 0.48

− 0.65, − 0.31

< 0.0001

 3 months

4

− 0.28

− 0.49, 0.08

0.007

 6 months

4

− 0.52

− 0.96, − 0.07

0.02

 ≥ 12 months

6

− 0.63

− 0.83, − 0.43

< 0.0001

 Peak VO2

4

0.94

− 3.15, 5.02

0.65

 MlHFQ

4

− 18.41

− 29.90, − 6.92

0.002

 MACE

6

0.79

0.60, 1.04

0.09

 Rehospitalization

5

0.71

0.49, 1.04

0.08

 All-cause mortality

17

0.74

0.56, 0.98

0.04

 Cardiovascular death

8

0.65

0.29, 1.46

0.29

  1. NYHA New York Heart Association, MlHFQ Minnesota Living with Heart Failure Questionnaire, MACE major adverse cardiovascular events